A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)

NCT04659161 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizophrenia; Psychosis

Interventions

DRUG: Xanomeline and Trospium Chloride Capsules
DRUG: Placebo

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company